Neuroone Medical Technologies (NMTC) Long-Term Deferred Tax (2018 - 2025)

Neuroone Medical Technologies (NMTC) has reported Long-Term Deferred Tax for 8 consecutive years, with $20.6 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Long-Term Deferred Tax rose 7.32% year-over-year to $20.6 million; the trailing twelve-month figure through Sep 2025 stood at $20.6 million (up 7.32% YoY), and the FY2025 full-year result was $20.6 million, up 7.32% from the prior year.
• Long-Term Deferred Tax rose to $20.6 million in Q3 2025 per NMTC's latest filing, from $19.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $20.6 million in Q3 2025 and bottomed at $8.9 million in Q3 2021.
• Historically, Long-Term Deferred Tax has averaged $15.3 million across 5 years, with a median of $15.6 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Long-Term Deferred Tax surged 55.81% in 2021, then climbed 7.32% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $8.9 million in 2021, then jumped by 35.9% to $12.1 million in 2022, then advanced by 29.65% to $15.6 million in 2023, then grew by 22.59% to $19.2 million in 2024, then rose by 7.32% to $20.6 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $20.6 million, $19.2 million, and $15.6 million for Q3 2025, Q3 2024, and Q3 2023 respectively.